CA Patent

CA2617213C — Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices

Assigned to Resverlogix Corp · Expires 2014-01-28 · 12y expired

What this patent protects

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammatio…

USPTO Abstract

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Drugs covered by this patent

Patent Metadata

Patent number
CA2617213C
Jurisdiction
CA
Classification
—
Expires
2014-01-28
Drug substance claim
No
Drug product claim
No
Assignee
Resverlogix Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.